VTGN (Vistagen Therapeutics) EBIT per Share : $-1.81 (TTM As of Mar. 2025)

View and export this data going back to 2009. Start your Free Trial

What is Vistagen Therapeutics EBIT per Share?

Vistagen Therapeutics's EBIT per Share for the three months ended in Mar. 2025 was $-0.46. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $-1.81.

During the past 3 years, the average EBIT per Share Growth Rate was 36.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 32.60% per year. During the past 10 years, the average EBIT per Share Growth Rate was 36.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Vistagen Therapeutics's EBIT per Share or its related term are showing as below:

VTGN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -609.5 Med: 31.3 Max: 49.4
Current: 36.9

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Vistagen Therapeutics was 49.40% per year. The lowest was -609.50% per year. And the median was 31.30% per year.

VTGN's 3-Year EBIT Growth Rate is ranked better than
80.9% of 1220 companies
in the Biotechnology industry
Industry Median: 9.35 vs VTGN: 36.90

Vistagen Therapeutics's EBIT for the three months ended in Mar. 2025 was $-14.50 Mil.

Vistagen Therapeutics EBIT per Share Historical Data

The historical data trend for Vistagen Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vistagen Therapeutics EBIT per Share Chart

Vistagen Therapeutics Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

EBIT per Share

Get a 7-Day Free Trial

-6.24

-7.24

-8.52

-1.71

-1.81

Vistagen Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT per Share	Get a 7-Day Free Trial															-0.42	-0.40	-0.46	-0.49	-0.46

Vistagen Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Vistagen Therapeutics's EBIT per Share for the fiscal year that ended in Mar. 2025 is calculated as

	EBIT per Share		(A: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-55.973	/	30.877
=	-1.81

Vistagen Therapeutics's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

	EBIT per Share		(Q: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-14.495	/	31.560
=	-0.46

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.81

Vistagen Therapeutics (NAS:VTGN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Vistagen Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Vistagen Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Vistagen Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vistagen Therapeutics Inc (NAS:VTGN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

343 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.vistagen.com

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Executives

Joshua S. Prince	officer: Chief Operating Officer	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Cynthia Lynn Anderson	officer: CHIEF FINANCIAL OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Jerry B Gin	director	343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Reid G. Adler	officer: CHIEF LEGAL OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94090
Shawn Singh	director, officer: CHIEF EXECUTIVE OFFICER	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Management Eg, Llc	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Healthcare Capital Partners Eg, L.p.	10 percent owner	3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Bong Y Koh	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Vhcp Co-investment Holdings Ii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Nimish P Shah	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036